Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22151226 | 0.88 | KISS1R (0.38) | PRMT6PRMT3CARM1PRMT1PRMT8 | |
| Trifluoroacetic Acid SCHEMBL9069011 | 0.88 | PRMT3 (0.33) | PRMT6PRMT3CARM1PRMT1PRMT8 | |
| SCHEMBL24607219 | 0.86 | KDM4A (0.38) | PRMT6PRMT3CARM1PRMT1PRMT8 | |
| SCHEMBL1831678 | 0.85 | PRMT3 (0.41) | PRMT6PRMT3CARM1PRMT1PRMT8 | |
| SCHEMBL23568414 | 0.84 | KDM4A (0.40) | PRMT6PRMT3CARM1PRMT1PRMT8 | |
| SCHEMBL16384281 | 0.84 | KDM4A (0.40) | PRMT6PRMT3CARM1PRMT1PRMT8 | |
| SCHEMBL7942433 | 0.81 | KDM4E (0.36) | CHRNB2CHRNB4CHRNA4DPP4PREP | |
| SCHEMBL127489 | 0.81 | DPP4 (0.33) | CHRNB2CHRNB4CHRNA4DPP4PREP | |
| SCHEMBL22906343 | 0.80 | MEN1 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL12457054 | 0.80 | KDM4A (0.34) | KISS1RHDAC6KDM4AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4413001-A1 | PARG INHIBITORY COMPOUNDS | FoRx Therapeutics AG (CH) | 2024-08-14 | — | — | EP | disclosed |
| CN-118055934-A | PARG inhibitory compounds | 福克斯治疗股份公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| WO-2023057389-A1 | PARG INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | PRMT6 3797/4885PRMT3 3610/4885CARM1 3244/4885 |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | PRMT6 2766/4885PRMT3 1358/4885CARM1 4392/4885 |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | TIMP3, AFG3L2, MMP3 | PRMT6 2766/4885PRMT3 1358/4885CARM1 4392/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | PRMT6 1718/4885PRMT3 1013/4885CARM1 894/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | PRMT6 2233/4885PRMT3 905/4885CARM1 892/4885 |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2A, RRM2B | PRMT6 950/4885PRMT3 676/4885CARM1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.